comparemela.com

Latest Breaking News On - Enz alone - Page 2 : comparemela.com

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all cohorts of patients including those recently.

United statesBritish columbiaAndrew laccettiDavid parkinsonDigital programEuropean society of medical oncologyPharma incDrug administrationMemorial sloan kettering cancer centerEuropean societyMedical oncologyEnz aloneMetastatic castration resistant prostate cancerCurrent phaseFast trackPrivate securities litigation reform act

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for.

British columbiaUnited statesDavid parkinsonAndrewl laccettiProstate cancer clinical trials working groupDrug administrationPharma incEuropean society of medical oncologyRecommended phaseEuropean societyMedical oncologyEnz aloneMetastatic castration resistant prostate cancerCurrent phaseFast trackPrivate securities litigation reform act

ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for.

United statesSan franciscoBritish columbiaAndrew leonard laccettiRussell kent pachynskiDavid parkinsonAsco gu digital programPharma incWashington university school of medicineMemorial sloan kettering cancer centerClinical oncology genitourinary cancers symposiumEnz aloneMetastatic castration resistant prostate cancerMemorial sloan kettering cancerProstate cancer foundation scientific retreatMetastatic castration resistant prostate

Updated Results from the Phase 1/2 Study of ESSA s Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for.

United statesBritish columbiaAndrew laccettiNan hyung hongDavid parkinsonPharma incProstate cancer foundationCancer foundationScientific retreatMetastatic castration resistant prostate cancerFirst in human dose escalation phaseEnz alonePreliminary resultsDose optimization componentFast trackPrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.